Sling Therapeutics, Inc.

71% of consumers use subscriptions to manage health and wellness goals SAN FRANCISCO, Dec. 20, 2023 /PRNewswire/ -- Just in time for New Year's resolutions, Recurly releases new consumer research showing the impact of subscriptions on the health and wellness journey of American consumers. 71% of consumers surveyed rely on subscriptions to help hit their health and wellness goals. The subscriptions consumers use range from biometric tracking and fitness apps to food delivery and weight management apps to prescription subscriptions and stress management apps. These findings and more explored the health and wellness priorities for 2024 as Recurly, the leading subscription management and billing platform, surveyed 1,000 U.S. adults for its new report, Recurly: Consumers Subscribe to Health in 2024. 2024's top resolutions—and subscriptions to support these resolutions—are below: In 2024, workout apps (33%) inched past gym memberships (32%) in popularity, followed closely by fitness trackers (30%). Stress management apps are rapidly emerging as a consumer choice, with 83% more individuals incorporating them into their 2024 plans compared to those who used it in 2023. Prescription subscriptions saw 22% year-over-year growth. "Subscriptions are the primary way that consumers are supporting their health and wellness goals in 2024", said Theresa McEndree, CMO at Recurly. "Consumers are prioritizing mental and physical health—and subscriptions play a vital role in supporting these resolutions. We are seeing exciting growth in this category in everything from weight management to nutritional support and meditation." There is a tremendous focus on health and wellness as a culture, and subscriptions are playing a vital role. Recurly supports many of the leading health and wellness subscriptions, offering a flexible platform for growth and HIPAA compliance. This is vital as subscription businesses scale, as many employers and insurance companies are starting to support health and wellness goals. Recurly works with health and wellness subscription businesses—everything from weight management to prescription subscriptions to consumer goods, such as nutraceuticals. Highlights from the survey include: The most popular health and wellness-related resolutions for 2024 indicate less focus on weight and a stronger focus on overall well-being. The highest-ranking goals were improving physical health (52%), improving mental health (44%) and losing weight (39%). Among those planning to lose weight in 2024, 26% are considering weight management apps, and 24% are considering weight management prescriptions and medications to help achieve their goals. Gen Z women and millennial moms are leading the mental health revolution. 56% of Gen Z respondents plan to improve their mental health in 2024. 58% of millennial moms want to do the same, and 48% want to effectively manage stress in 2024. Among baby boomers, only 25% have the goal of improving their mental health. When asked about the impact on health and wellness from using subscription services in 2023, nearly three-quarters of respondents (71%) said they saw improvement, with 22% saying it led to significant improvement. 58% of all respondents said they plan to spend under $50 per month on health and wellness apps, and 26% of Gen Z and millennials plan to spend $101 or more per month. To read the full Recurly: Consumers Subscribe to Health in 2024, click here. About Recurly Thousands of innovative companies across digital media, streaming, publishing, SaaS, education, consumer goods, and professional services industries rely on Recurly to unlock transformational growth using subscriptions. Recurly's all-in-one, integrated platform removes the complexities of automating subscription billing at scale by enabling teams to manage and optimize their subscriber lifecycles with ease. Category-defining companies including Sling, Twitch, BarkBox, FabFitFun, Paramount, Lucid, and Sprout Social have chosen Recurly to manage billions of dollars in recurring revenues, future-proof their recurring billing and revenue management, and recover billions of dollars in lost revenue due to churn. Founded in 2009, Recurly is based in San Francisco, with offices in Boulder and London. For more information, visit . SOURCE Recurly

ANN ARBOR, Mich., Nov. 8, 2023 /PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating in three upcoming investor conferences in November 2023. Details of the presentations can be found below. Stifel 2023 Healthcare Conference Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Tuesday, November 14, at 9:45 a.m. ET. BTIG 3rd Annual Ophthalmology Day Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Monday, November 27, at 3:30 p.m. ET. Piper Sandler Healthcare Conference Chief Executive Officer, Ryan Zeidan, Ph.D., will present a company presentation and host 1x1 investor meetings on Wednesday, November 29, at 9:50 a.m. ET. About Sling Therapeutics Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED. For more information visit . Investor Contact Jessica Vo Gilmartin Group, LLC [email protected] Media Contact Adam Daley Berry & Company Public Relations 212.253.8881 [email protected] SOURCE Sling Therapeutics

- Linsitinib inhibited the formation of CD4+ T-cells in bone marrow, which are upregulated and clinically relevant in Thyroid Eye Disease (TED) - - Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of active, moderate to severe TED will provide clinical context and relevance - ANN ARBOR, Mich., Sept. 25, 2023 /PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the publication of new preclinical data demonstrating linsitinib reduced pathologic bone marrow activity in a mouse model of TED. The data have been published in the peer-review journal Frontiers in Endocrinology. "As TED develops in patients, autoreactive CD4+ T-cells migrate into the bone marrow, inducing activation of the bone marrow and consecutive myelopoiesis. These latest preclinical data showed treatment with linsitinib significantly inhibited the activation pathway by blocking myeloid cells traveling to the thyroid and orbit, and directly induced arginase-1 in the bone marrow, leading to a depletion of arginine," said Anja Eckstein, M.D., professor and head of the Department of Orthoptics, Oculoplastic and Reconstructive Surgery and Orbital Center at the University Eye Hospital Essen, Germany. "Given that T-cells require arginine to activate and proliferate properly, the number of CD4+ T-cells in the bone marrow significantly decreased following treatment with linsitinib, resulting in reduced inflammation and tissue damage." "This recent dataset reinforces Sling's deep commitment to preclinical work designed to better elucidate the role of linsitinib as a potential first-line oral drug to treat all stages of TED," said Jeffrey Kent, M.D., Chief Medical Officer of Sling Therapeutics. "Abnormal bone marrow activity has been implicated in multiple autoimmune diseases, where the role of cytokine production via increased hematogenesis exacerbates clinical disease. We are pleased to be among first to demonstrate the effect of IGF-1R inhibition on this process and we are even more delighted to demonstrate that linsitinib markedly reduces pro-inflammatory cytokines which are released due to upregulated activity of hematopoietic stem and progenitor cells (HSPC). We look forward to translating these preclinical results in our ongoing global Phase 2b LIDS trial." The preclinical study investigated the effect of linsitinib on bone marrow activity in mice immunized with a plasmid encoding the A-subunit of thyroid stimulating hormone receptor (TSHR). Analyses of treated bone marrow showed downregulation of multiple cytokines associated with TED and upregulation of arginase-1. For more information about the Phase 2b LIDS trial, visit . About Thyroid Eye Disease (TED) TED is a debilitating autoimmune disease that affects about 20,000 people in the U.S. per year and has a similar prevalence in Europe. Dysfunction in the IGF-1R signaling pathway leads to a prevalence of thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) that drive excess fibrous tissue growth behind the eyes. The inflammation can push the eyes forward or cause the eyes and eyelids to become red and swollen. As the disease progresses it can lead to pain, eye bulging, and double vision. TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease. About Sling Therapeutics Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED. For more information visit . Investor Contact Jessica Vo Gilmartin Group, LLC [email protected] Media Contact Adam Daley Berry & Company Public Relations 212.253.8881 [email protected] SOURCE Sling Therapeutics